0 382

Cited 2 times in

The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer

DC FieldValueLanguage
dc.contributor.author심효섭-
dc.contributor.author이창영-
dc.contributor.author장준-
dc.contributor.author정인경-
dc.contributor.author정지예-
dc.contributor.author조병철-
dc.contributor.author김대준-
dc.contributor.author김세규-
dc.contributor.author김은영-
dc.contributor.author김주항-
dc.contributor.author김혜련-
dc.contributor.author김효송-
dc.contributor.author박지수-
dc.date.accessioned2016-02-04T11:21:26Z-
dc.date.available2016-02-04T11:21:26Z-
dc.date.issued2015-
dc.identifier.issn0169-5002-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/140244-
dc.description.abstractOBJECTIVES: Fibroblast growth factor receptor 1 (FGFR1) plays a critical role in many human cancers. We tried to identify the frequency of FGFR1 amplifications among Korean patients with small cell lung cancer (SCLC). Additionally, we examined the clinical significance of FGFR1 amplifications for overall survival (OS) and progression-free survival (PFS) among SCLC patients who received standard chemotherapies. MATERIALS AND METHODS: Tumor tissues from 158 Korean patients diagnosed with SCLC from September 2009 to February 2013 were collected and analyzed using an FGFR1 FISH assay with a probe that hybridized to chromosome region 8p12-8p11.23 (Abbott Molecular, Abbott Park, IL). RESULTS AND CONCLUSION: FGFR1 amplification was detected in three patients (1.9%) harboring extensive disease (ED). A multivariate analysis showed that among the patients with ED, FGFR1 amplification was associated with shorter disease-free survival to first-line chemotherapy with etoposide plus cisplatin or carboplatin (hazard ratio [HR]=7.1; 95% confidence interval [CI]=2.0-25.4; P=0.003). The median overall survival time of the patients with ED was 8.2 and 10.2 months among patients with and without FGFR1 amplification, respectively (P=0.37). Although FGFR1 amplification is rare in SCLC compared to non-small cell lung cancer or other malignancies with squamous histology, it is associated with poor survival following standard chemotherapy in SCLC. Further studies in large cohorts of patients with SCLC are needed to verify these results. Our results imply that FGFR1 may be a potential therapeutic target in SCLC and it could be confirmed in a clinical trial.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfLUNG CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHBiomarkers-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHGene Amplification*-
dc.subject.MESHHumans-
dc.subject.MESHIn Situ Hybridization, Fluorescence-
dc.subject.MESHLung Neoplasms/genetics*-
dc.subject.MESHLung Neoplasms/mortality*-
dc.subject.MESHLung Neoplasms/pathology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHOutcome Assessment (Health Care)-
dc.subject.MESHPrognosis-
dc.subject.MESHReceptor, Fibroblast Growth Factor, Type 1/genetics*-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRisk Factors-
dc.subject.MESHSmall Cell Lung Carcinoma/genetics*-
dc.subject.MESHSmall Cell Lung Carcinoma/mortality*-
dc.subject.MESHSmall Cell Lung Carcinoma/pathology-
dc.titleThe frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Thoracic & Cardiovascular Surgery (흉부외과학)-
dc.contributor.googleauthorJi Soo Park-
dc.contributor.googleauthorJae-Seok Lee-
dc.contributor.googleauthorEun Young Kim-
dc.contributor.googleauthorJi Ye Jung-
dc.contributor.googleauthorSe Kyu Kim-
dc.contributor.googleauthorJoon Chang-
dc.contributor.googleauthorDae Joon Kim-
dc.contributor.googleauthorChang Young Lee-
dc.contributor.googleauthorInkyung Jung-
dc.contributor.googleauthorJoo Hang Kim-
dc.contributor.googleauthorHye Ryun Kim-
dc.contributor.googleauthorYong Wha Moon-
dc.contributor.googleauthorHyo Song Kim-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorHyo Sup Shim-
dc.identifier.doi10.1016/j.lungcan.2015.03.002-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02219-
dc.contributor.localIdA03245-
dc.contributor.localIdA03472-
dc.contributor.localIdA03693-
dc.contributor.localIdA03735-
dc.contributor.localIdA03822-
dc.contributor.localIdA00368-
dc.contributor.localIdA00602-
dc.contributor.localIdA00945-
dc.contributor.localIdA01166-
dc.contributor.localIdA01202-
dc.contributor.localIdA00811-
dc.relation.journalcodeJ02174-
dc.identifier.eissn1872-8332-
dc.identifier.pmid25819384-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0169500215001543-
dc.subject.keywordAmplification-
dc.subject.keywordBiomarker-
dc.subject.keywordFGFR1-
dc.subject.keywordFISH-
dc.subject.keywordPrognosis-
dc.subject.keywordSmall cell lung cancer-
dc.contributor.alternativeNameShim, Hyo Sup-
dc.contributor.alternativeNameLee, Chang Young-
dc.contributor.alternativeNameChang, Joon-
dc.contributor.alternativeNameJung, In Kyung-
dc.contributor.alternativeNameJung, Ji Ye-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.alternativeNameKim, Dae Joon-
dc.contributor.alternativeNameKim, Se Kyu-
dc.contributor.alternativeNameKim, Eun Young-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNameKim, Hye Ryun-
dc.contributor.alternativeNameKim, Hyo Song-
dc.contributor.affiliatedAuthorShim, Hyo Sup-
dc.contributor.affiliatedAuthorLee, Chang Young-
dc.contributor.affiliatedAuthorChang, Joon-
dc.contributor.affiliatedAuthorJung, In Kyung-
dc.contributor.affiliatedAuthorJung, Ji Ye-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.contributor.affiliatedAuthorKim, Dae Joon-
dc.contributor.affiliatedAuthorKim, Se Kyu-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorKim, Hye Ryun-
dc.contributor.affiliatedAuthorKim, Hyo Song-
dc.contributor.affiliatedAuthorKim, Eun Young-
dc.rights.accessRightsnot free-
dc.citation.volume88-
dc.citation.number3-
dc.citation.startPage325-
dc.citation.endPage331-
dc.identifier.bibliographicCitationLUNG CANCER, Vol.88(3) : 325-331, 2015-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.